Endothelial progenitor cells : a new real hope?
This book explores the role of endothelial progenitor cells (EPCs) in the context of regenerative medicine (RegMed). In particular, it reveals the value of RegMed as a new TM branch intended to improve the health and quality of life, by restoring, maintaining or enhancing tissue and functions of org...
Saved in:
| Main Author | |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Cham :
Springer,
2017.
|
| Series | UNIPA Springer series.
|
| Subjects | |
| Online Access | Full text |
| ISBN | 9783319551074 9783319551067 |
| Physical Description | 1 online resource (99 pages) |
Cover
Table of Contents:
- Preface; Acknowledgements; Contents; About the Author; Acronyms; 1 From Regenerative Medicine to Endothelial Progenitor Cells as Potential Candidates; Abstract; 1.1 Regenerative Medicine: A New Branch of Translational Medicine; 1.1.1 Stem Cell Therapy; 1.1.2 Stem Cells as Appropriate Candidates of Cell Therapy: Types of Stem Cell; 1.2 Endothelial Progenitor Cells: Other Emerging Candidates for RegMed Therapeutic Treatment; 1.2.1 Evidence of Several Circulating Subpopulations of EPCs; 1.2.2 EPCs: from BM progenitors to mature EC cells.
- 1.3 Phenotypic Markers and Levels of Circulating EPCs in Adult Subjects1.3.1 EPC Quantification Using Flow Cytometry and Its Limitation; 1.3.2 Factors Modulating EPC Quantitative and Qualitative Evaluation by Flow Cytometry; 1.3.3 Pathological or Physiological Conditions as Factors Able to Modulate EPC Quantitative and Qualitative Evaluation; 1.4 The Complex Process of Regulation of EPC Biology and Function: New Insights on the Key Role of Notch, ROS and Wnt Pathways and Their Crosstalk, and Epigenetics; 1.5 Conclusions; Acknowledgements; References.
- 2 Endothelial Progenitor Cells and Their Clinical Applications as Potential Disease Biomarkers and Therapeutic Agents: Evidence and Controversies Regarding Their EffectivenessAbstract; 2.1 Endothelial Dysfunction as the Early Event of Chronic Age-Related Diseases: EPCs as Cellular Biomarkers; 2.2 Relationship Between Circulating EPC Levels and Age-Related Diseases; 2.2.1 Unfavorable Factors Associated with Decreased Circulating EPC Levels; 2.2.2 Physiological Factors and High Circulating EPC Levels; 2.2.3 Exogenous Measures as Potential Strategies for Increasing Circulating EPC Levels.
- 2.3 Correlation Between Blood EPC Levels and Cardiovascular Profile2.3.1 Atherosclerosis; 2.3.2 Hypertension; 2.3.3 Coronary Artery Disease (CAD); 2.3.4 Bicuspid Aortic Valve, Aortic Valve Regurgitation (AR) and Aneurysm; 2.3.5 Cerebral Ischemia; 2.3.6 Other CVD Diseases; 2.4 EPCs in Alzheimer Disease; 2.5 Diabetes and EPCs; 2.6 EPCs in Solid and Hematological Cancers, and Recent Controversies Relating to Their Incorporation into Tumor Neovessels; 2.7 EPCs as Therapeutic Agents; 2.7.1 EPCs as Therapeutic Agents for CVDs: Focus on Ischemic Disease Treatment, Capacity and Doubts.
- 2.7.2 The Clinical Results and Indications of Autologous Therapies2.8 EPCs as Therapeutic Agents for Cancer: Focus on Anti-VEGF Treatments and Controversies in Their Efficacy; 2.9 EPCs as Therapeutic Agents for Alzheimer's Disease; 2.10 EPCs as Therapeutic Agents for Diabetes; 2.11 Controversies About EPC Use as Optimal Candidates for Cell Therapy; 2.12 Conclusions and Perspectives; References; 3 Endothelial Progenitor Cells: A Real Hope or an Unrealizable Dream? Which Measures or Strategies Are Necessary for making EPCs a clinical reality? Focus on a Potential Roadmap; Abstract.